An antifibrinolytic strategy for the treatment of hemorrhage
Hemostatics Pharmaceuticals S.L. (Hemostatics) is a biotechnology company recently promoted by the Cima Universidad de Navarra, specialized in the preclinical and clinical development of a new antifibrinolytic agent.
The company was created in August 2020 by a team of highly specialized experts in the health, science, and business sectors. Its goal is to develop CM-352, a novel, proprietary antifibrinolytic agent to reduce bleeding in life-threatening and disabling bleeding conditions.
CM-352 is an optimized compound highly effective in preclinical models in major bleeding scenarios associated with major surgery, trauma, intracerebral hemorrhage (ICH), or other tissue damage. It has also been shown to be safe and without associated acute toxicity.
Hemostatic seeks to address an important unmet medical need by using an innovative mechanism of action to inhibit fibrinolysis. The Hemostatic team is actively working to complete the preclinical development plan and be ready to move to Phase 1, while in parallel securing funding.